NASDAQ:NGNE Neurogene (NGNE) Stock Price, News & Analysis $19.95 +0.34 (+1.73%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$19.94 0.00 (-0.03%) As of 09/5/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Neurogene Stock (NASDAQ:NGNE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neurogene alerts:Sign Up Key Stats Today's Range$19.58▼$20.6750-Day Range$14.95▼$23.0952-Week Range$6.88▼$74.49Volume195,596 shsAverage Volume103,511 shsMarket Capitalization$284.69 millionP/E RatioN/ADividend YieldN/APrice Target$46.17Consensus RatingModerate Buy Company Overview Neurogene, Inc. is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions. Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues. Preclinical studies have demonstrated the potential for sustained biochemical correction and functional improvement, supporting the company’s progression into human clinical trials. Initial studies are under way in North America, and Neurogene plans to expand its clinical footprint into Europe pending regulatory clearances. Headquartered in South San Francisco, California, Neurogene was founded to address the unmet needs of patients and families living with life-threatening genetic disorders of the nervous system. The company’s executive leadership team brings together expertise in gene therapy development, neurology, and biopharmaceutical manufacturing. By targeting diseases with well-defined genetic causes and no approved treatments, Neurogene aims to deliver transformative therapies to patients worldwide.AI Generated. May Contain Errors. Read More Neurogene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreNGNE MarketRank™: Neurogene scored higher than 48% of companies evaluated by MarketBeat, and ranked 599th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingModerate Buy Consensus RatingNeurogene has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialNeurogene has a consensus price target of $46.17, representing about 131.4% upside from its current price of $19.95.Amount of Analyst CoverageNeurogene has only been the subject of 2 research reports in the past 90 days.Read more about Neurogene's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neurogene are expected to grow in the coming year, from ($4.27) to ($4.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurogene is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurogene is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeurogene has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neurogene's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted22.06% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 15.6, which indicates bearish sentiment.Change versus previous monthShort interest in Neurogene has recently increased by 2.70%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurogene does not currently pay a dividend.Dividend GrowthNeurogene does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted22.06% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 15.6, which indicates bearish sentiment.Change versus previous monthShort interest in Neurogene has recently increased by 2.70%, indicating that investor sentiment is decreasing. News and Social Media2.9 / 5News Sentiment1.26 News SentimentNeurogene has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Neurogene this week, compared to 4 articles on an average week.Search Interest2 people have searched for NGNE on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neurogene insiders have not sold or bought any company stock.Percentage Held by Insiders11.64% of the stock of Neurogene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurogene's insider trading history. Receive NGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NGNE Stock News HeadlinesNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5 at 4:01 PM | businesswire.comAnalysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $46.17August 27, 2025 | americanbankingnews.comCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.September 6 at 2:00 AM | SmartAsset (Ad)Neurogene Advances NGN-401 Gene Therapy for Rett SyndromeAugust 14, 2025 | theglobeandmail.comNeurogene Inc. Reports Increased Losses Amid R&D FocusAugust 11, 2025 | tipranks.comNeurogene Reports Second Quarter 2025 Financial Results and Highlights Recent UpdatesAugust 11, 2025 | businesswire.comNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2025 | businesswire.comBullish Neurogene Insiders Loaded Up On US$1.46m Of StockJuly 30, 2025 | finance.yahoo.comSee More Headlines NGNE Stock Analysis - Frequently Asked Questions How have NGNE shares performed this year? Neurogene's stock was trading at $22.86 at the start of the year. Since then, NGNE shares have decreased by 12.7% and is now trading at $19.95. How were Neurogene's earnings last quarter? Neurogene Inc. (NASDAQ:NGNE) issued its earnings results on Monday, August, 11th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.15) by $0.10. Who are Neurogene's major shareholders? Top institutional investors of Neurogene include Redmile Group LLC (8.95%), Commodore Capital LP (3.00%), Geode Capital Management LLC (1.74%) and Jennison Associates LLC (1.18%). Insiders that own company stock include Samsara Biocapital Gp, Llc, Rachel Mcminn, Christine Mikail Cvijic and Stuart Cobb. View institutional ownership trends. How do I buy shares of Neurogene? Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neurogene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurogene investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Disc Medicine (IRON). Company Calendar Last Earnings8/11/2025Today9/06/2025Next Earnings (Estimated)11/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NGNE Previous SymbolNASDAQ:NGNE CIK1404644 Webwww.neurogene.com Phone(877) 237-5020Fax778-331-4486Employees90Year FoundedN/APrice Target and Rating Average Price Target for Neurogene$46.17 High Price Target$72.00 Low Price Target$24.00 Potential Upside/Downside+131.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($4.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$75.14 million Net MarginsN/A Pretax Margin-8,742.70% Return on Equity-33.33% Return on Assets-30.34% Debt Debt-to-Equity RatioN/A Current Ratio18.07 Quick Ratio18.07 Sales & Book Value Annual Sales$930 thousand Price / Sales306.11 Cash FlowN/A Price / Cash FlowN/A Book Value$20.89 per share Price / Book0.96Miscellaneous Outstanding Shares14,270,000Free Float12,611,000Market Cap$284.69 million OptionableOptionable Beta1.58 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:NGNE) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWarren Buffett's Strangest AI InvestmentTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredOdd trade could help investors secure their wealth in 2025The most profitable phrase you’ve never heard of... Have you heard of 310F? This simple string of code coul...Eagle Publishing | SponsoredNewegg (NEGG) Earns BULLISH Rating – Up 934%The last time he shared a free AI stock pick like this, it soared 100%.Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.